It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss drug Zepbound through a new partnership with Eli Lilly. | Direct-to-consumer health and wellness company Ro will now offer access to lower-priced,

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an integrated platform with home delivery.

Ro today announced it is working with Eli Lilly and Company to streamline access to Zepbound® (tirzepatide) single-dose vials for Ro patients with obesity. The vials will be available as a treatment option with an on-label prescription from a Ro-affiliated provider via an integration with the LillyDirect® self-pay pharmacy channel.

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound. Ro Health is joining other telehealth platforms and Amazon Pharmacy (AMZN) in giving patients access to Lilly's top GLP-1 product by plugging in to the pharmaceutical giant's new direct-to-consumer platform,